France Biotech News

tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.

Bromodomains are a new emerging class of pharmaceutical targets in the field of Epigenetics. Bromodomains (BRDs) are protein domains involved in Epigenetics that recognize acetylated lysines.

Stimulated Emission Depletion Microscopy (or STED nanoscopy) offers a technological breakthrough in the environment of cell imaging by drastically increasing the resolution over traditional confocal microscopy.

The most reliable method to accurately measure the wavelength of pulsed lasers.

Magnetofectamine™ is the association of Lipofectamine™ 2000 the most renowned transfection reagent from Life Technologies Corporation (Invitrogen™) with the unique Magnetofection™ based reagent CombiMag, from OZ Biosciences™.

CYTOO, a company that specializes in micropattern-enhanced cell-based assays, Cenix BioScience, a pioneer in developing HCS applications of RNAi, and three European academic partners to challenge the current limits of HT RNAi cell screening.

tebu-bio is pleased to announce their recent distribution agreement with Sanguine BioSciences, Inc.

Ocean Optics, is proud to announce that, expanding the potential applications for its oxygen and pH sensing patches, Ocean Optics has obtained United States Pharmacopeia (USP) Class VI certification for these products.

tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.

Bromodomains are a new emerging class of pharmaceutical targets in the field of Epigenetics. Bromodomains (BRDs) are protein domains involved in Epigenetics that recognize acetylated lysines.

Stimulated Emission Depletion Microscopy (or STED nanoscopy) offers a technological breakthrough in the environment of cell imaging by drastically increasing the resolution over traditional confocal microscopy.

The most reliable method to accurately measure the wavelength of pulsed lasers.

HypoThermosol® and CryoStor® Will Be Locally Available to the Broader European Research and Clinical Markets

tebu-bio and XenoTech LLC co-organize a series of webinars focused on attaching human hepatocytes in ADME-TOX studies.

Magnetofectamine™ is the association of Lipofectamine™ 2000 the most renowned transfection reagent from Life Technologies Corporation (Invitrogen™) with the unique Magnetofection™ based reagent CombiMag, from OZ Biosciences™.

CYTOO, a company that specializes in micropattern-enhanced cell-based assays, Cenix BioScience, a pioneer in developing HCS applications of RNAi, and three European academic partners to challenge the current limits of HT RNAi cell screening.

Grenoble, France – CYTOO SA announced today the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner also participated.

The Kima™ pump is a microfluidic pump designed to aid cell culture (e.g. endothelial cells) under physiological conditions (shear flow) in various biochips and flow chambers.

tebu-bio is pleased to announce their recent distribution agreement with Sanguine BioSciences, Inc.

Ocean Optics, is proud to announce that, expanding the potential applications for its oxygen and pH sensing patches, Ocean Optics has obtained United States Pharmacopeia (USP) Class VI certification for these products.

Après Madrid, Santiago du Chili et Genève, Strasbourg se dote d’une académie de la coiffure entièrement pensée dans le respect de l’environnement et du bien-être des collaborateurs

tebu-bio is pleased to be participating at the ELA Screening Europe conference which will take place in Hamburg from June 30th to July 1st, 2011

CYTOO sponsors the first edition of the World Cell Race. Organized by a network of researchers in partnership with the American and the French Cell Biology Societies, this unique competition will involve cells coming from labs all around the globe.

tebu-bio is pleased to announce the renewal for another three years, of their official recognition by the French Ministry of Higher Education & Research as an approved CRO (contract research organisation) within the French Research Tax Credit scheme.

tebu-bio is pleased to announce their recent distribution agreement with Cellix Ltd.

The new generation of antimicrobial confirmed its potential with the evidence of effectiveness on this resistant bacterium kindly provided by Harvard Children's Hospital for which no therapeutic solution is available to date

The Steering and Scientific Committees are pleased to announce the availability of the preliminary program of the 5th International Workshop on HIV Persistence, Reservoirs and Eradication Strategies.

AIR SÛR, leading french company in air tratment since 1994, has developped a new mobile solution using UV-C photocatalisis for air decontamination in homes and for profesionals exposed in their working environment.

BFi OPTiLAS, pan-European partner of Ocean Optics, is introducing a family of concave grating spectrometers that delivers scientific-grade stray light performance, stability and optical bench throughput.

Meiogenix and CIRAD signed a collaboration agreement to evaluate the impact of Meiogenix’s SpiX™ technology in modulating meiotic homologous recombination in rice leading to the identification of new varieties of rice with commercial potential.

BFi OPTiLAS’ team, partner of Labsphere is proud to announce, the availability of a new software routine allowing sunscreens to be characterized per the latest global in-vitro testing standards.

tebu-bio is pleased to announce the renewal of their agreement with Advanced Biotechnologies for the distribution of their products throughout Europe.

Meiogenix SAS, a French start-up biotech company developing of a new genomic technology, closed its first round of financing of 1,2M ! from Kurma Biofund, a French venture capital fund focused in Life Sciences.

Since the launch of their first mini-website dedicated to SilenciX, tebu-bio has subsequently released sites focussed on Preadipocytes and Antibody Arrays, with the most recent addition now centered around CryostaX™.

CYTOO Cell Architects today announced the commercial release of CYTOOplates™ 96 that bring robustness, sensitivity and powerful quantification to cell-based assays and High Content Screening.

tebu-bio will be attending the forthcoming ISNN congress "From reference intakes to personalized nutrition", which will take place in Pamplona, Spain, from November 18th to 20th, 2010.

tebu-bio (Le Perray en Yvelines, France) is pleased to enter an agreement with Arbor Assays LLC, (Ann Arbor, USA) for the distribution of their products to a large number of European countries.

BFi OPTiLAS, Pan-European partner of Precision Photonics, now offers a new range of broadband low dispersion polarizers and super broadband polarizing beamsplitter cubes.

tebu-bio is pleased to be attending the Hepatocyte User Group & Medicon Valley Hepatocytes User Forum which will take place in Montpellier, France, on October 22nd and 23rd 2010.

EMAUD, the only complete and innovative course on pharmaceutical Market Access designed around the life cycle of a drug, is starting its second academic year on October 2010.

Constantly seeking to enrich their range of laboratory services, tebu-bio is now offering Life Sciences researchers a standardized protein expression optimisation service in E. coli.

tebu-bio has developped a new service entitled ExpressiX, bringing researchers the opportunity to obtain stable, ready-to-use cell lines with controlled, targeted gene integration.

LifeSensors and tebu-bio today announced that they have entered into an agreement under which tebu-bio will be LifeSensors' sole European distributor.

BFi OPTiLAS, the largest Photonic distributor in Europe, is announcing the availability of high volume, low cost injection molded Light Shaping Diffuser lenses for LED lighting products.

Genomic Vision has signed an agreement with AFM (French Association against Muscular Dystrophy) and has received a grant for validation of diagnostic test and further understanding of FSHD

Alaxia is glad to announce that its medicinal product candidate Hypothiocyanite (OSCN) / Lactoferrin developed under the brand name Meveol, received Orphan drug designation for the treatment of cystic fibrosis (CF) by the US FDA .

tebu-bio announces the launch of their new website, providing European Life Sciences Researchers with a powerful tool to help them in their research

CYTOO SA, a provider of innovative enabling technologies for high content cell analysis, premiered what it believes is the world's first commercially available portfolio of cell adhesive micropattern products to the cell biology research community.

Biospace Lab announces new distributors in China & Taiwan and appointment of an Asia/Pacific support office

tebu-bio (Le Perray en Yvelines, France) and Platypus Technologies (Madison, USA) are pleased to announce their agreement to have tebu-bio distribute the Platypus Oris™ kits throughout Europe.

Dr André Sobczyk (Protein Production Manager - tebu-bio), will be presenting the innovative protein production platform developed by tebu-bio laboratories at the Protein Congress 2008 in Berlin, on November 20th and 21st 2008.

tebu-bio, in partnership with SABiosciences (Frederick, MD), is pleased to announce the launch of SilenciX cell lines in the USA

Dr. Ali el Bayâ (Sales Manager - tebu-bio Germany) will be presenting SilenciX at the forthcoming 12th STS Meeting 2008: Signal Transduction – Receptors, Mediators and Genes, in Weimar (DE) from October 29th to 31st 2008.

tebu-bio is pleased to announce their laboratories have recently received official recognition from the French Ministry of Higher Education and Research as an approved CRO (contract research organisation) within the French Research Tax Credit scheme.

Nadia Normand (BioAssay Manager - tebu-bio Laboratories) will be presenting the SilenciX cell lines at the upcoming 5th annual RNAi Europe conference, which will be held from September 16th to 18th in Stockholm and is dedicated to RNA interference.

tebu-bio celebrates 10 years serving the ADME community in Paris in Autumn (October 9th, 2008; Maison de la Chimie, France).

Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its catalogue.